{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:59:17Z","timestamp":1792760357228,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ygyno.2020.08.015","type":"journal-article","created":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T16:09:26Z","timestamp":1598198966000},"page":"509-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients"],"prefix":"10.1016","volume":"159","author":[{"given":"Sarah G.","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan L.","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lynn","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley M.","family":"Kidwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.08.015_bb0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast Cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0015","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","article-title":"Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast Cancer: American Society of Clinical Oncology clinical practice guideline focused update","volume":"32","author":"Burstein","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0020","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fonc.2019.00359","article-title":"Anti-estrogen treatment in endometrial Cancer: a systematic review","volume":"9","author":"Weelden","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0025","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1525-1438.2007.01075.x","article-title":"Aromatase inhibitors in ovarian cancer: is there a role?","volume":"18","author":"Li","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0030","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/IGC.0000000000000334","article-title":"Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status","volume":"25","author":"Stasenko","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0040","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1158\/1078-0432.CCR-16-1501","article-title":"Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens","volume":"23","author":"Andersen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00002512-199813040-00008","article-title":"Anastrozole","volume":"13","author":"Wiseman","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0050","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/cncr.10908","article-title":"An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane","volume":"95","author":"Buzdar","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0055","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.amjsurg.2006.06.018","article-title":"Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective","volume":"192","author":"Garreau","year":"2006","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0060","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/1534735415596573","article-title":"Acupuncture for aromatase inhibitor\u2013induced arthralgia: a systematic review","volume":"14","author":"Bae","year":"2015","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0065","article-title":"Aromatase Inhibitor--Associated Musculoskeletal Symptoms: Etiology and Strategies for Management","volume":"22","author":"Henry","year":"2008","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/bcr2818","article-title":"Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management","volume":"13","author":"Gaillard","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0075","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00520-017-3613-z","article-title":"Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis","volume":"25","author":"Beckw\u00e9e","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0080","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/acr.21756","article-title":"Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study","volume":"64","author":"Singer","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0085","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.2015.63.8619","article-title":"Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of Tamoxifen and Letrozole, Alone and in Sequence","volume":"34","author":"Chirgwin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0090","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","article-title":"Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review","volume":"134","author":"Murphy","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0095","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.2011.38.0261","article-title":"Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer","volume":"30","author":"Henry","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jbi.2015.05.003","article-title":"Supporting information retrieval from electronic health records: a report of University of Michigan\u2019s nine-year experience in developing and using the electronic medical record search engine (EMERSE)","volume":"55","author":"Hanauer","year":"2015","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0110","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2007.10.7573","article-title":"Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer","volume":"25","author":"Crew","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0115","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clbc.2017.03.002","article-title":"Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation","volume":"17","author":"Henry","year":"2017","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0120","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.24419","article-title":"Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors","volume":"115","author":"Mao","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1345\/aph.1R369","article-title":"Effect of concurrent prescription antiarthralgia pharmacotherapy on persistence to aromatase inhibitors in treatment-naive postmenopausal females","volume":"47","author":"Hashem","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0130","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.57.1547","article-title":"Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors","volume":"33","author":"Irwin","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0135","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-018-4946-0","article-title":"Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927)","volume":"172","author":"Shen","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0140","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2017.74.6651","article-title":"Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated Arthralgias in early-stage breast Cancer: SWOG S1202","volume":"36","author":"Henry","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.015_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.32024","article-title":"Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202","author":"Henry","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0150","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0155","first-page":"181","article-title":"Threats to validity in retrospective studies","volume":"3","author":"Tofthagen","year":"2012","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0160","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(09)70114-7","article-title":"The brief pain inventory: revealing the effect of cancer pain","volume":"10","author":"Bennett","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2020.08.015_bb0165","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1188\/13.ONF.549-557","article-title":"Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors","volume":"40","author":"Swenson","year":"2013","journal-title":"Oncol. Nurs. Forum"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820338166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820338166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T04:04:04Z","timestamp":1715832244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820338166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0090825820338166"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}